Literature DB >> 26187868

PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement.

Doen Ming Ong1, Katherine D Cummins1, Alan Pham2, George Grigoriadis3.   

Abstract

A 55-year-old man with a history of well controlled HIV infection was admitted with acute renal impairment, peripheral oedema, constitutional symptoms, deranged liver function and hypercalcaemia. Core biopsies of a retroperitoneal mass demonstrated anaplastic lymphoma kinase (ALK) negative anaplastic large cell lymphoma (ALCL) with unusual Paired box 5 (PAX5) positivity. The same malignant cells were identifiable on urine cytology. Staging investigations revealed extensive nodal and extranodal disease including ALK negative ALCL involving the kidney and prostate, which has not previously been reported in the published literature. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26187868      PMCID: PMC4513530          DOI: 10.1136/bcr-2015-211159

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  37 in total

1.  Gross hematopyuria presenting as a first symptom due to the bladder infiltration of extranodal Burkitt's lymphoma.

Authors:  Hideaki Fujiwara; Jun Odawara; Brian Hayama; Yoko Takanashi; Kan-ichi Iwama; Masayuki Yamakura; Masami Takeuchi; Kosei Matsue
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

2.  Anaplastic large cell lymphoma: a unique presentation with urinary bladder involvement: a case report.

Authors:  Amanda J Murphy; Paul O'Neill; Frank O'Brien; Helen Enright; Michael Jeffers; John A Thornhill; Barbara M Loftus
Journal:  Int J Surg Pathol       Date:  2005-10       Impact factor: 1.271

Review 3.  Human Immunodeficiency Virus-associated anaplastic large cell lymphoma.

Authors:  Kimberly Perez; Jorge Castillo; Bruce J Dezube; Liron Pantanowitz
Journal:  Leuk Lymphoma       Date:  2010-03

4.  Ki-1-positive large cell anaplastic lymphoma diagnosed by urinary cytology. A case report.

Authors:  T Tanaka; N Yoshimi; K Sawada; T Takami; S Sugie; F Etori; H Kachi; H Mori
Journal:  Acta Cytol       Date:  1993 Jul-Aug       Impact factor: 2.319

5.  Anaplastic lymphoma masquerading as sclerosing mesenteritis: a case report.

Authors:  Jay Luther; Alexander J Faje; Mahmoud Al-Hawary; John Y Kao
Journal:  J Gastrointest Cancer       Date:  2012-06

6.  Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.

Authors:  R Suzuki; Y Kagami; K Takeuchi; M Kami; M Okamoto; R Ichinohasama; N Mori; M Kojima; T Yoshino; H Yamabe; M Shiota; S Mori; M Ogura; N Hamajima; M Seto; T Suchi; Y Morishima; S Nakamura
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

Authors:  Norbert Schmitz; Lorenz Trümper; Marita Ziepert; Maike Nickelsen; Anthony D Ho; Bernd Metzner; Norma Peter; Markus Loeffler; Andreas Rosenwald; Michael Pfreundschuh
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

Review 8.  Diagnostic uses of Pax5 immunohistochemistry.

Authors:  Andrew L Feldman; Ahmet Dogan
Journal:  Adv Anat Pathol       Date:  2007-09       Impact factor: 3.875

Review 9.  Anaplastic Large Cell Lymphoma.

Authors:  L Jeffrey Medeiros; Kojo S J Elenitoba-Johnson
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

Review 10.  Pax5: the guardian of B cell identity and function.

Authors:  César Cobaleda; Alexandra Schebesta; Alessio Delogu; Meinrad Busslinger
Journal:  Nat Immunol       Date:  2007-05       Impact factor: 25.606

View more
  1 in total

1.  PAX5-Negative Classical Hodgkin Lymphoma: A Case Report of a Rare Entity and Review of the Literature.

Authors:  Elham Vali Betts; Denis M Dwyre; Huan-You Wang; Hooman H Rashidi
Journal:  Case Rep Hematol       Date:  2017-10-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.